It ain't over 'til the fat lady sings.
The antiatherogenic drug nicotinic acid (niacin) has antidyslipidemic effects independent of free fatty acid suppression mediated by its receptor HCA₂ (GPR109A) (Lauring et al., this issue).
Department of Pharmacology, Max Planck Institute for Heart and Lung Research, Ludwigstr. 43, 61231 Bad Nauheim, Germany. stefan.offermanns@mpi-bn.mpg.de
Stefan
S
Offermanns
D000818:Animals; D005227:Fatty Acids / Q000378:metabolism*; D006801:Humans; D008297:Male; D009525:Niacin / Q000494:pharmacology*; D043562:Receptors, G-Protein-Coupled / Q000378:metabolism*; D011978:Receptors, Nicotinic / Q000378:metabolism*
D005227:Fatty Acids; C530636:HCAR2 protein, human; C473652:Hcar2 protein, mouse; D043562:Receptors, G-Protein-Coupled; D011978:Receptors, Nicotinic; D009525:Niacin